This afternoon, I'm screening the bottom of the barrel for value. Fundamentals.
Criteria
Hooper Holmes (HH)
Stock price: 0.82 (May 21, 2010)
Sales: 176.8m
Profit margin: 0.6%
Profile: Healthcare company, assists insurance companies.
Key info: CEO makes 508K. Growth slowed (-11.6%). Cash 17.7m. No debt. Stats are mostly positive. 14.2% owned by insiders, 67% owned by instututions. Float 62m.
Criteria
• below $10
• prior year sales positive
• 1-yr sales growth 50% or more
• prior year's net income positive
• price-to-book 5.0+
There are six stocks that fit the criteria. Now I'll see if any of them has zero debt.
Osiris Theraputics (OSIR)
Stock price: 6.24 (May 21, 2010)
Profile: stem cell/biotech.
Key info: Growth prospects negative, but debt is minimal ($1,000). Majority of shares (53%) owned by insiders. Keep watching. CEO makes 605K.
Grade: D
http://finance.yahoo.com/q/ks?s=OSIR+Key+Statistics
Sharps Compliance (SMED)
Stock price: 5.60 (May 21, 2010)
Profile: medical waste solutions
Key info: Profitable, excellent return on assets and equity, but yoy revenue growth down 39%. Cash 19.8m, debt 0. 34.91% of shares held by insiders, 33% by institutions. Tiny float: 9.13m. CEO pay not listed; VP of sales/marketing 250k.
Grade: B. The only minus is yoy rev growth (recession?). Why isn't the CEO pay made public?
http://finance.yahoo.com/q/ks?s=SMED+Key+Statistics
Keryx Biopharmeceuticals (KERX)
Stock price: 4.98 (May 21, 2010)
Profile: biotech
Key info: No debt, revenue growth -100%. Cash 33.93m. Drug in development/Phase III. Stock was 34¢ in February. Without FDA approval, could easily drop back to 1.00. Float 54m. CEO makes 295k; principal financial officer 340k.
Grade: B-
http://finance.yahoo.com/q/ks?s=KERX+Key+Statistics
Immunomedics (IMMU)
Stock price: 3.34 (May 21, 2010)
Profile: biotech (health care/diagnostic substances)
Key info: Phase III clinical trial products for cancer. Cash 24.85m, no debt. No listed negative stats. Float is 63.15m. Only 8% owned by insiders, 34.4% by institutions. CEO makes 692k, CFO 416k, founder/chairman/chief scientific officer 700k.
Grade: B-
http://finance.yahoo.com/q/ks?s=immu
Biodelivery Sciences International (BDSI)
Stock price: 2.94 (May 21, 2010)
Profile: biotech
Key info: Onsolis approved by FDA for pain caused by cancer. Bema Buprenorphine in Phase II development. Cash: 23.87m, debt "N/A". Float 16.32m. Rev: 62.8m. No info on CEO pay ("N/A")
Grade: C. Worth a look even though the debt issue and CEO pay are very sketchy.
http://finance.yahoo.com/q/ks?s=BDSI+Key+Statistics
Symntroleum (SYNM)
Stock price: 2.02 (May 21, 2010)
Profile: oil/gas refining and marketing
Key info: Rev 11.48m, cash 26.81m, debt "N/A". CEO makes 1.58m! Lot of negatives in the stats. Float is 65m.
Grade: D
http://finance.yahoo.com/q/ks?s=SYNM+Key+Statistics
• prior year sales positive
• 1-yr sales growth 50% or more
• prior year's net income positive
• price-to-book 5.0+
There are six stocks that fit the criteria. Now I'll see if any of them has zero debt.
Osiris Theraputics (OSIR)
Stock price: 6.24 (May 21, 2010)
Profile: stem cell/biotech.
Key info: Growth prospects negative, but debt is minimal ($1,000). Majority of shares (53%) owned by insiders. Keep watching. CEO makes 605K.
Grade: D
http://finance.yahoo.com/q/ks?s=OSIR+Key+Statistics
Sharps Compliance (SMED)
Stock price: 5.60 (May 21, 2010)
Profile: medical waste solutions
Key info: Profitable, excellent return on assets and equity, but yoy revenue growth down 39%. Cash 19.8m, debt 0. 34.91% of shares held by insiders, 33% by institutions. Tiny float: 9.13m. CEO pay not listed; VP of sales/marketing 250k.
Grade: B. The only minus is yoy rev growth (recession?). Why isn't the CEO pay made public?
http://finance.yahoo.com/q/ks?s=SMED+Key+Statistics
Keryx Biopharmeceuticals (KERX)
Stock price: 4.98 (May 21, 2010)
Profile: biotech
Key info: No debt, revenue growth -100%. Cash 33.93m. Drug in development/Phase III. Stock was 34¢ in February. Without FDA approval, could easily drop back to 1.00. Float 54m. CEO makes 295k; principal financial officer 340k.
Grade: B-
http://finance.yahoo.com/q/ks?s=KERX+Key+Statistics
Immunomedics (IMMU)
Stock price: 3.34 (May 21, 2010)
Profile: biotech (health care/diagnostic substances)
Key info: Phase III clinical trial products for cancer. Cash 24.85m, no debt. No listed negative stats. Float is 63.15m. Only 8% owned by insiders, 34.4% by institutions. CEO makes 692k, CFO 416k, founder/chairman/chief scientific officer 700k.
Grade: B-
http://finance.yahoo.com/q/ks?s=immu
Biodelivery Sciences International (BDSI)
Stock price: 2.94 (May 21, 2010)
Profile: biotech
Key info: Onsolis approved by FDA for pain caused by cancer. Bema Buprenorphine in Phase II development. Cash: 23.87m, debt "N/A". Float 16.32m. Rev: 62.8m. No info on CEO pay ("N/A")
Grade: C. Worth a look even though the debt issue and CEO pay are very sketchy.
http://finance.yahoo.com/q/ks?s=BDSI+Key+Statistics
Symntroleum (SYNM)
Stock price: 2.02 (May 21, 2010)
Profile: oil/gas refining and marketing
Key info: Rev 11.48m, cash 26.81m, debt "N/A". CEO makes 1.58m! Lot of negatives in the stats. Float is 65m.
Grade: D
http://finance.yahoo.com/q/ks?s=SYNM+Key+Statistics
Now a new screen.
• $1 or lower
• minimum $100m sales
• positive profit margin
8 stocks qualify. One is already listed above: AZZ, which had 357m in sales and one of the highest profit margins (10.6%) of these sub-$1 stocks.
AutoInfo (AUTO.OB)
Stock price: 0.45 (May 21, 2010)
Sales: 183.9m
Profit margin: 0.8%
Profile: services/trucking
Key info: CEO pay "N/A". Growth slowed (-21.8%). Cash 67k. Debt is 18.65m. 73% of shares held by insiders. Float 8.97m.
Grade: D
http://finance.yahoo.com/q/ks?s=AUTO.OB+Key+Statistics
Compton Petroleum (CMZ)
Stock price: 0.71 (May 21, 2010)
Sales: 190m
Profit margin: 12.9%
Profile: oil/gas drilling and exploration
Key info: Debt is 554m. Mixed signals on stats. Operating margin -27%. Float 252m, 2.3% owned by insiders, 39% owned by institutions. CEO is paid 578K.
Grade: D+
http://finance.yahoo.com/q/ks?s=CMZ+Key+Statistics
Footstar (FTAR.OB)
Stock price: 0.32 (May 21, 2010)
Sales: 462.1m
Profit margin: 11.5%
Profile: "Footstar, Inc. is in the process of liquidation and dissolution pursuant to the plan approved by the company's Board of Directors on March 5, 2009." No officers available.
Key info: How did a bankrupt company have such a healthy profit margin? Goes to show how useless that particular statistic is. I can only imagine how much execs got paid before Chapter 7.
Grade: n/a
http://finance.yahoo.com/q/pr?s=FTAR.OB+Profile
• $1 or lower
• minimum $100m sales
• positive profit margin
8 stocks qualify. One is already listed above: AZZ, which had 357m in sales and one of the highest profit margins (10.6%) of these sub-$1 stocks.
AutoInfo (AUTO.OB)
Stock price: 0.45 (May 21, 2010)
Sales: 183.9m
Profit margin: 0.8%
Profile: services/trucking
Key info: CEO pay "N/A". Growth slowed (-21.8%). Cash 67k. Debt is 18.65m. 73% of shares held by insiders. Float 8.97m.
Grade: D
http://finance.yahoo.com/q/ks?s=AUTO.OB+Key+Statistics
Compton Petroleum (CMZ)
Stock price: 0.71 (May 21, 2010)
Sales: 190m
Profit margin: 12.9%
Profile: oil/gas drilling and exploration
Key info: Debt is 554m. Mixed signals on stats. Operating margin -27%. Float 252m, 2.3% owned by insiders, 39% owned by institutions. CEO is paid 578K.
Grade: D+
http://finance.yahoo.com/q/ks?s=CMZ+Key+Statistics
Footstar (FTAR.OB)
Stock price: 0.32 (May 21, 2010)
Sales: 462.1m
Profit margin: 11.5%
Profile: "Footstar, Inc. is in the process of liquidation and dissolution pursuant to the plan approved by the company's Board of Directors on March 5, 2009." No officers available.
Key info: How did a bankrupt company have such a healthy profit margin? Goes to show how useless that particular statistic is. I can only imagine how much execs got paid before Chapter 7.
Grade: n/a
http://finance.yahoo.com/q/pr?s=FTAR.OB+Profile
Hooper Holmes (HH)
Stock price: 0.82 (May 21, 2010)
Sales: 176.8m
Profit margin: 0.6%
Profile: Healthcare company, assists insurance companies.
Key info: CEO makes 508K. Growth slowed (-11.6%). Cash 17.7m. No debt. Stats are mostly positive. 14.2% owned by insiders, 67% owned by instututions. Float 62m.
Grade: B, but does new fed policy on health care kill HH?
http://finance.yahoo.com/q/ks?s=HH+Key+Statistics
Integrated Healthcare (IHCH.OB)
Stock price: 0.07 (May 21, 2010)
Sales: 392m
Profit margin: 0.5%
Profile: owns/operates hospitals/health care facilities in Orange County, Calif. This was a 1¢ stock in July '09. CEO is paid 144k. CFO paid 422k. COO 422k. Consultant 529k.
Key info: Debt is 87m. Cash is 4.2m.
Grade: D+
http://finance.yahoo.com/q/ks?s=IHCH.OB+Key+Statistics
Radiant Logistics (RLGT.OB)
Stock price: 0.27 (May 21, 2010)
Sales: 135m
Profit margin: 0.7%
Profile: Air delivery, freight services.
Key info: CEO pay "N/A", COO 180k. Cash 478k. Debt is 8.7m. Float 18.6m. 50% owned by insiders. 0.80% owned by institutions.
Grade: D
http://finance.yahoo.com/q/ks?s=RLGT.OB+Key+Statistics
Tigrent (TIGE.OB)
Stock price: 0.35 (May 21, 2010)
Sales: 170m
Profit margin: 5.9%
Profile: Education/training services.
Key info: CEO paid 84k; CFO paid 286k. Cash 10.7m. Debt 5.5m. Shares outstanding 11.7m, float 6.5m. No info on insider and institutional holding. Growth stats positive.
Grade: B-. I like that the execs are not overpaid.
http://finance.yahoo.com/q/ks?s=TIGE.OB+Key+Statistics
http://finance.yahoo.com/q/ks?s=HH+Key+Statistics
Integrated Healthcare (IHCH.OB)
Stock price: 0.07 (May 21, 2010)
Sales: 392m
Profit margin: 0.5%
Profile: owns/operates hospitals/health care facilities in Orange County, Calif. This was a 1¢ stock in July '09. CEO is paid 144k. CFO paid 422k. COO 422k. Consultant 529k.
Key info: Debt is 87m. Cash is 4.2m.
Grade: D+
http://finance.yahoo.com/q/ks?s=IHCH.OB+Key+Statistics
Radiant Logistics (RLGT.OB)
Stock price: 0.27 (May 21, 2010)
Sales: 135m
Profit margin: 0.7%
Profile: Air delivery, freight services.
Key info: CEO pay "N/A", COO 180k. Cash 478k. Debt is 8.7m. Float 18.6m. 50% owned by insiders. 0.80% owned by institutions.
Grade: D
http://finance.yahoo.com/q/ks?s=RLGT.OB+Key+Statistics
Tigrent (TIGE.OB)
Stock price: 0.35 (May 21, 2010)
Sales: 170m
Profit margin: 5.9%
Profile: Education/training services.
Key info: CEO paid 84k; CFO paid 286k. Cash 10.7m. Debt 5.5m. Shares outstanding 11.7m, float 6.5m. No info on insider and institutional holding. Growth stats positive.
Grade: B-. I like that the execs are not overpaid.
http://finance.yahoo.com/q/ks?s=TIGE.OB+Key+Statistics
I'm not interested in buying any of this, hell no. But I'm interested in the ones that show potential, have zero debt. Then I'll dig more and more and more. If there's anything I've learned about tiny stocks, pennies, etc. is that they tend to be scammish in nature (not all). Just look at how little they generate in revenue and how much their executives skim off the top. They don't give a shit about shareholders. They're good at it, too.
There are also those pennies that were one-day or one-week wonders. Xybernaut (XYBR) was going to develop a computer system built into eyewear, perfect for all kinds of work. Right... Then there was Skins Inc. (SKNN), which made a shoe that you could fold up and carry around. Why the hell anyone wants to carry folding footwear, I do not know, but there were plenty of Kool-Aid drinkers.
There's a reason why most pennies are almost worthless. That should tell you everything you need to know. But that being said, there is always going to be a gem or two in the rough, a stock that is clearly undervalued. That's why I dig.
No comments:
Post a Comment